Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide Monotherapy in Relapsed/Refractory B-cell NHL
NCT03245905Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2017
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in B-cell non-Hodgkin lymphoma, sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03245905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03245905.